BioForce Nanosciences Reports Q2 2026 Financial Results, Transition to Oil and Gas Sector

BioForce Nanosciences Holdings, Inc. reported its financial results for the second quarter of 2026, revealing a significant shift in its operational focus and financial performance. The company, which previously operated in the nutritional supplement sector, transitioned to the oil and gas industry as of June 5, 2026. For the three months ending June 30, 2026, BioForce recorded a net income of $238,682, a notable improvement compared to a net loss of $122,781 during the same period in 2025. For the six months ended June 30, 2026, the company reported a net income of $136,271, contrasting sharply with a net loss of $1,058,238 in the prior year.

The financial statements indicate that BioForce's total assets increased to $2,388,075 as of June 30, 2026, up from $786,000 at the end of 2025. This increase was primarily driven by the acquisition of oil and gas leases valued at $234,525 and a substantial rise in prepaid expenses amounting to $2,153,243. The company's total liabilities decreased significantly to $84,767 from $619,329, largely due to the forgiveness of debt totaling $502,373 by a board member, which contributed to the positive net income reported for the quarter.

Operationally, BioForce has not generated any sales revenue from its previous product lines or its new oil and gas ventures during the reported periods. The company has not received any orders for its BioForce Eclipse supplement product, nor has it engaged in oil or gas production. However, the transition to the oil and gas sector is expected to involve further geological studies and the potential drilling of exploratory wells on the newly acquired leases, which cover approximately 19,957 acres in Nevada.

The company’s strategic developments included a change in management, with Richard Kaiser appointed as interim CEO following the resignation of the previous co-CEOs. Additionally, BioForce established an advisory board and appointed two members to assist in its new direction. The company’s financial health remains a concern, as it reported an accumulated deficit of $162,275,846 and indicated that it will require additional capital to sustain operations and implement its business plan effectively. The management expressed optimism about the potential for future revenue generation but acknowledged the uncertainty surrounding its ability to continue as a going concern without further financing.